Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

The sFlt1/PlGF ratio predicts faster fetal deterioration in early fetal growth restriction: A historical cohort study.

Palma Dos Reis CR. et al, (2023), Acta Obstet Gynecol Scand

Novel therapeutic and diagnostic approaches for preeclampsia.

Vatish M. et al, (2023), Curr Opin Nephrol Hypertens, 32, 124 - 133

Preeclampsia and syncytiotrophoblast membrane extracellular vesicles (STB-EVs).

Awoyemi T. et al, (2022), Clin Sci (Lond), 136, 1793 - 1807

The prognostic utility of soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PIGF) biomarkers for predicting preeclampsia: a secondary analysis of data from the INSPIRE trial.

Kifle MM. et al, (2022), BMC Pregnancy Childbirth, 22

Paracetamol use in pregnancy — neglecting context promotes misinterpretation

O’Sullivan J. et al, (2022), Nature Reviews Endocrinology

Ruling out preeclampsia in the next 4 weeks using a soluble fms-like tyrosine kinase 1/placental growth factor ratio ≤38: secondary analysis of the Interventional Study on Prediction of Preeclampsia/Eclampsia in Women With Suspected Preeclampsia

Cerdeira AS. et al, (2022), American Journal of Obstetrics and Gynecology, 226, 443 - 445

Retroperitoneal leiomyomatosis: a benign outcome of power morcellation with potentially serious consequences

Cerdeira AS. et al, (2022), The Lancet, 399, 554 - 554

Is Prolonging Gestation in Preeclampsia For Better or Worse in Preventing Cardiovascular Disease?

Cerdeira AS. et al, (2021), Hypertension, 78, 1395 - 1397

The diagnostic value of angiogenic and antiangiogenic factors in differential diagnosis of preeclampsia.

Cerdeira AS. et al, (2021), Am J Obstet Gynecol

Performance of soluble fms-like tyrosine kinase-1–to–placental growth factor ratio of ≥85 for ruling in preeclampsia within 4 weeks

Cerdeira AS. et al, (2021), American Journal of Obstetrics and Gynecology, 224, 322 - 323

In vivo evidence of significant placental growth factor release by normal pregnancy placentas

Cerdeira AS. et al, (2020), Scientific Reports, 10

The value of MRI in management of uterine fibroids in pregnancy

Cerdeira AS. et al, (2020), European Journal of Obstetrics & Gynecology and Reproductive Biology

One Step Closer to a Cure for Preeclampsia?

Cerdeira AS. et al, (2020), Hypertension, 76, 1081 - 1083

Specimen Requirements for Preeclampsia Markers.

Smith I. et al, (2020), The journal of applied laboratory medicine, 5, 605 - 607

Predictive Accuracy of Soluble FMS-Like Tyrosine Kinase-1/Placental Growth Factor Ratio for Preeclampsia in Japan: A Systematic Review

Yamazaki T. et al, (2020), Hypertension Research in Pregnancy

Predictive Performance of PlGF (Placental Growth Factor) for Screening Preeclampsia in Asymptomatic Women

Agrawal S. et al, (2019), Hypertension, 74, 1124 - 1135

Seeing red degeneration in uterine fibroids in pregnancy: proceed with caution

Cerdeira AS. et al, (2019), The Lancet, 394, e37 - e37

Maternal circulating syncytiotrophoblast-derived extracellular vesicles contain biologically active 5’-tRNA halves

Cooke WR. et al, (2019), Biochemical and Biophysical Research Communications, 518, 107 - 113

Randomized Interventional Study on Prediction of Preeclampsia/Eclampsia in Women With Suspected Preeclampsia

Cerdeira AS. et al, (2019), Hypertension, 74, 983 - 990

Maternal circulating syncytiotrophoblast-derived extracellular vesicles contain biologically active 5’-tRNA halves

Cooke WR. et al, (2019)

Load More

Include forthcoming?